To gauge at which phase in the disease trajectory the two new Parkinson’s disease-linked miRNAs hsa-miR-132-3p/-5p and hsa-miR-129-5p show the strongest degree of differential expression, we assessed their association with α-synuclein and tau Braak staging in the brains of Parkinson’s disease patients (for the distribution of Braak and tau staging in the Parkinson’s disease brains, see Supplementary Table S1). The gene discussed is MAPT; the disease is Parkinson disease.